Combining tocilizumab and sarilumab along with corticosteroids reduced the risk of death by 17% compared with corticosteroids alone.
CIDRAP: WHO Advises 2 Monoclonal Antibodies For Severe COVID The World Health Organization (WHO) today recommended the use of anti-inflammatory monoclonal antibodies—tocilizumab and sarilumab—alongside corticosteroids for treating patients who have severe or critical COVID-19 infections. … They found that the interleukin-6 antagonists tocilizumab and sarilumab reduced the risk of death and the need for mechanical ventilation. The WHO coordinated the study, which included partners from the United Kingdom. (Schnirring, 7/6)